Skip to main content
micro-community-banner
 
  • Saved

made a Post

Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC - PubMed

1 Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis And Thoracic Tumor Research Institute, Beijing, China. 2 Medical Department, Amoy Diagnostics Co., Ltd., Xiamen, China. 3 Department ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33656807/

  • Saved

from Pathologist Connect made a Post

Thrilled to be a part of this Hackathon. Brainstorming new treatments for #lungcancer Join us if you can help
https://cancerhackerlab.com/linnea-olson/
see more

Linnea olson - CancerHacker Lab

Linnea Olson is a well-known advocate for patients and a pioneer in clinical trials for lung cancer. She was diagnosed with non-small cell lung cancer in April of 2005. Linnea ..... see more

Source : https://cancerhackerlab.com/linnea-olson/

  • Saved

made a Post

Treatment Patterns and Survival of Patients With Advanced Non-Small Cell Lung Cancer Guided by Comprehensive Genomic Profiling: Real-World Single-Institute Study in China - PubMed

Although the National Comprehensive Cancer Network and the Chinese Society of Clinical Oncology guidelines recommend comprehensive genomic profiling of lung adenocarcinoma, it has not been widely applied in Chinese hospitals. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33777783/

  • Saved

made a Post

Second drug targeting KRASG12C shows benefit in mutated non-small-cell lung cancer

Clinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) harbouring this mutation, according to results from ..... see more

Source : https://www.eurekalert.org/pub_releases/2021-03/esfm-sdt032321.php

  • Saved

made a Post

Implementation of CRISPR/Cas9 Genome Editing to Generate Murine Lung Cancer Models That Depict the Mutational Landscape of Human Disease - PubMed

Lung cancer is the most common cancer worldwide and the leading cause of cancer-related deaths in both men and women. Despite the development of novel therapeutic interventions, the 5-year survival ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33738287/

  • Saved

made a Post

Targeting KRAS: The Elephant in the Room of Epithelial Cancers - PubMed

Mutations of the proto-oncogene KRAS are the most frequent gain-of-function alterations found in cancer. KRAS is mutated in about 30% of all human tumors, but it could reach more than ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33777798/

  • Saved

made a Post

STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications - PubMed

Across cancers, STK11 alterations correlated with a poor prognosis regardless of therapy. However, STK11 alterations alone did not associate with inferior immunotherapy outcome in the pan-cancer setting or in NSCLC. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33744718/

  • Saved

made a Post

Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung Cancer [ELCC 2021 Virtual Press Release]

LUGANO, Switzerland; DENVER, CO, USA - Clinical activity with a second drug inhibiting KRAS G12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) ..... see more

Source : https://www.esmo.org/newsroom/press-office/second-drug-targeting-kras-g12c-shows-benefit-in-mutated-non-small-cell-lung-cancer

  • Saved

made a Post

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)

KRAS, an oncogenic driver in lung cancer, is known as an "undruggable" target Different strategies are under investigation to indirectly and directly target KRAS Clinical trials of small-molecule inhibitors report ..... see more

Source : https://www.sciencedirect.com/science/article/pii/S266637912030241X

  • Saved

made a Post

The Prevalence and Concurrent Pathogenic Mutations of KRAS G12C in Northeast Chinese Non-small-cell Lung Cancer Patients - PubMed

1 Medical Oncology Translational Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Lung Cancer, Jilin Cancer Hospital, Changchun, 130012, People's Republic of China. 2 Department of Medical Thoracic ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33758543/

  • Saved

made a Post

The origins and genetic interactions of KRAS mutations are allele- and tissue-specific - PubMed

Mutational activation of KRAS promotes the initiation and progression of cancers, especially in the colorectum, pancreas, lung, and blood plasma, with varying prevalence of specific activating missense mutations. Although epidemiological ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33753749/

  • Saved

made a Post

60-Year-Old Professor with Increasing Fatigue

A 60-year-old immunology professor presents complaining of increasing fatigue over the past 3-to-4 months. She had a cough for a couple of weeks that ..... see more

  • Saved

from Pathologist Connect made a Post

Adagrasib yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C–mutant advanced non–small cell lung cancer.
..... see more

Adagrasib Demonstrates Favorable Efficacy, Pharmacokinetic Profile in Advanced KRAS G12C+ NSCLC

Adagrasib (MRTX849) yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C-mutant advanced non-small cell lung cancer, ..... see more

Source : https://www.onclive.com/view/adagrasib-demonstrates-favorable-efficacy-pharmacokinetic-profile-in-advanced-kras-g12c-nsclc

  • Saved

from Pathologist Connect made a Post

Second drug targeting KRASG12C shows benefit in mutated non-small-cell lung cancer

see more

Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung Cancer [ELCC 2021 Virtual Press Release]

LUGANO, Switzerland; DENVER, CO, USA - Clinical activity with a second drug inhibiting KRAS G12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) ..... see more

Source : https://www.esmo.org/newsroom/press-office/second-drug-targeting-kras-g12c-shows-benefit-in-mutated-non-small-cell-lung-cancer

  • Saved

made a Post

Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy - PubMed

Droplet digital polymerase chain reaction (ddPCR) is a highly sensitive and accurate method for quantification of nucleic acid sequences. We used absolute quantification of mutated v-Ki-ras2 Kirsten rat sarcoma viral ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33502820/

  • Saved

made a Post

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy - PubMed

doi: 10.1158/1535-7163.MCT-20-0462. Online ahead of print. 1 Research, Mirati Therapeutics (United States). 2 cancer center, New York University School of Medicine. 3 Research - Biology, Mirati Therapeutics (United States). 4 ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33722854/

  • Saved

made a Post

KRAS G12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma - PubMed

1 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Infectious Diseases and Pulmonary Medicine, Berlin, Germany. 2 Helios ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/33718018/

  • Saved

made a Post

The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation

Peter Radeczky, 1, 2 Zsolt Megyesfalvi, 1, 2, 3 Viktoria Laszlo, 2, 3 Janos Fillinger, 1, 2 Judit Moldvay, 2, 4 Erzsebet Raso, 5 Erzsebet Schlegl, 2 Tamas Barbai, 5 ..... see more

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947398/

  • Saved

from Pathologist Connect made a Post

"Asked about adoption in the clinic if the drug gains approval, Li said the first step will be to start testing all NSCLC patients for KRAS mutations."
..... see more

KRAS Inhibitor Continues to Impress in NSCLC

More than a third of patients with pretreated non-small cell lung cancer (NSCLC) and a KRAS G12C mutation responded to the investigational agent sotorasib, findings from a phase II study ..... see more

Source : https://www.medpagetoday.com/meetingcoverage/iaslc/90989

  • Saved

from Pathologist Connect made a Post

This is scary.

“More than one in 10 patients with lung cancer do not know what type of tumour they have.”

Educated patients ..... see more

More Than One in 10 Patients With Lung Cancer Do Not Know What Type They Have [ESMO Press Release]

LUGANO, Switzerland; DENVER, CO, USA - More than one in 10 patients with lung cancer do not know what type of tumour they have, according to data from a 17-country ..... see more

Source : https://www.esmo.org/newsroom/press-office/more-than-one-in-10-patients-with-lung-cancer-do-not-know-what-type-they-have